Trubenbacher L, Lindenberg N, Graf B, Backmund M, Unglaub W, Lassen C
J Pain Res. 2024; 17:1067-1076.
PMID: 38505502
PMC: 10948325.
DOI: 10.2147/JPR.S421841.
Heidbreder C, Fudala P, Greenwald M
Drug Alcohol Depend Rep. 2023; 6:100133.
PMID: 36994370
PMC: 10040330.
DOI: 10.1016/j.dadr.2023.100133.
Warren D, Marashi A, Siddiqui A, Eijaz A, Pradhan P, Lim D
PLoS One. 2022; 17(12):e0278988.
PMID: 36520864
PMC: 9754174.
DOI: 10.1371/journal.pone.0278988.
Bergen A, Baurley J, Ervin C, McMahan C, Bible J, Stafford R
Int J Environ Res Public Health. 2022; 19(7).
PMID: 35409790
PMC: 8998781.
DOI: 10.3390/ijerph19074106.
Lim J, Farhat I, Douros A, Panagiotoglou D
PLoS One. 2022; 17(3):e0266142.
PMID: 35358261
PMC: 8970369.
DOI: 10.1371/journal.pone.0266142.
French-Canadian Translation and Cultural Adaptation of the Clinical Opiate Withdrawal Scale: The COWS-FC.
Bruneau A, Poirier C, Berube M, Boulanger A, Gelinas C, Guenette L
Can J Psychiatry. 2022; 67(9):701-711.
PMID: 35290134
PMC: 9449138.
DOI: 10.1177/07067437221087066.
Ambulatory detoxification in alcohol use disorder and opioid use disorder.
Moore T
Ment Health Clin. 2020; 10(6):307-316.
PMID: 33224688
PMC: 7653729.
DOI: 10.9740/mhc.2020.11.307.
Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.
Goedel W, Shapiro A, Cerda M, Tsai J, Hadland S, Marshall B
JAMA Netw Open. 2020; 3(4):e203711.
PMID: 32320038
PMC: 7177200.
DOI: 10.1001/jamanetworkopen.2020.3711.
Buprenorphine/Naloxone Maintenance Therapy: an Observational Retrospective Report on the Effect of Dose on 18 months Retention in an Office-Based Treatment Program.
Parran T, Mace A, Dahan Y, Adelman C, Kolganov M
Subst Abuse. 2017; 11:1178221817731320.
PMID: 29051703
PMC: 5638148.
DOI: 10.1177/1178221817731320.
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Kosloski M, Zhao W, Asatryan A, Kort J, Geoffroy P, Liu W
Antimicrob Agents Chemother. 2017; 61(10).
PMID: 28807904
PMC: 5610490.
DOI: 10.1128/AAC.00958-17.
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
Gray K, Sonne S, McClure E, Ghitza U, Matthews A, McRae-Clark A
Drug Alcohol Depend. 2017; 177:249-257.
PMID: 28623823
PMC: 5535813.
DOI: 10.1016/j.drugalcdep.2017.04.020.
Buprenorphine for managing opioid withdrawal.
Gowing L, Ali R, White J, Mbewe D
Cochrane Database Syst Rev. 2017; 2:CD002025.
PMID: 28220474
PMC: 6464315.
DOI: 10.1002/14651858.CD002025.pub5.
Novel Therapeutics for Addiction: Behavioral and Neuroeconomic Approaches.
Bickel W, Mellis A, Snider S, Moody L, Stein J, Quisenberry A
Curr Treat Options Psychiatry. 2016; 3(3):277-292.
PMID: 28018836
PMC: 5176106.
DOI: 10.1007/s40501-016-0088-3.
Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003.
Barbosa-Leiker C, McPherson S, Mamey M, Burns G, Layton M, Roll J
Drug Alcohol Depend. 2015; 152:218-23.
PMID: 25908321
PMC: 4458161.
DOI: 10.1016/j.drugalcdep.2015.03.036.
Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
Dunn K, Saulsgiver K, Miller M, Nuzzo P, Sigmon S
Drug Alcohol Depend. 2015; 151:47-55.
PMID: 25823907
PMC: 4447545.
DOI: 10.1016/j.drugalcdep.2015.02.033.
Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.
Bentzley B, Barth K, Back S, Book S
J Subst Abuse Treat. 2015; 52:48-57.
PMID: 25601365
PMC: 4382404.
DOI: 10.1016/j.jsat.2014.12.011.
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Mattick R, Breen C, Kimber J, Davoli M
Cochrane Database Syst Rev. 2014; (2):CD002207.
PMID: 24500948
PMC: 10617756.
DOI: 10.1002/14651858.CD002207.pub4.
Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents.
Ziaaddini H, Nasirian M, Nakhaee N
Addict Health. 2014; 4(3-4):79-86.
PMID: 24494140
PMC: 3905537.
A comparison of the efficacy of buprenorphine and clonidine in detoxification of heroin-dependents and the following maintenance treatment.
Ziaaddini H, Nasirian M, Nakhaee N
Addict Health. 2014; 2(1-2):18-24.
PMID: 24494096
PMC: 3905506.
Psychometric properties of the adjective rating scale for withdrawal across treatment groups, gender, and over time.
Barbosa-Leiker C, McPherson S, Mamey M, Burns G, Roll J
J Subst Abuse Treat. 2013; 46(2):251-6.
PMID: 24074852
PMC: 3870009.
DOI: 10.1016/j.jsat.2013.08.020.